← Browse by Condition
Medical Condition
marginal zone lymphoma
Total Trials
6
Recruiting Now
6
Trial Phases
Phase 2, Phase 1, Phase 2, Phase 3
NCT05281809 Phase 2
Recruiting
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Enrollment
30 pts
Location
United States
Sponsor
John Lister
NCT05006716 Phase 1, Phase 2
Recruiting
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Enrollment
614 pts
Location
United States, Austr...
Sponsor
BeOne Medicines
NCT05805605 Phase 2
Recruiting
Allo HSCT Using RIC and PTCy for Hematological Diseases
Enrollment
56 pts
Location
United States
Sponsor
Masonic Cancer Center, Univers...
NCT06504940 Phase 2
Recruiting
Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)
Enrollment
69 pts
Location
China
Sponsor
First Affiliated Hospital of Z...
NCT06454968 Phase 2
Recruiting
Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
Enrollment
45 pts
Location
China
Sponsor
Peking Union Medical College H...
NCT07029217 Phase 3
Recruiting
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
Enrollment
375 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...